Somnus Therapeutics was a private specialty pharmaceutical company based in Bedminster, United States. The company's lead product, SKP-1041, was a controlled-release formulation of an established non-benzodiazepine hypnotic, licensed from SkyePharma, aimed at preventing mid-night awakenings without next-day hangovers
Insomnia
CTI LSF I
Co-Lead
Director
February 9, 2010
Liquidated in 2015
Series A
Somnus Therapeutics' lead asset could addresses the two key issues of existing insomnia treatments, patients waking up at the middle of the night and waking up the next day drowsy
February 11, 2010
